Radiolabeled Protein-inhibitor Peptides with Rapid Clinical Translation Towards Imaging and Therapy

(E-pub Ahead of Print)

Author(s): Guillermina Ferro-Flores*, Blanca Ocampo-García, Myrna Luna Gutiérrez, Clara Santos Cuevas, Nallely Jiménez-Mancilla, Erika Azorín-Vega, Laura Meléndez-Alafort.

Journal Name: Current Medicinal Chemistry

Become EABM
Become Reviewer


Protein interactions are the basis for the biological functioning of human beings. However, many of these interactions are also responsible for diseases, including cancer. Synthetic inhibitors of protein interactions based on small molecules are widely investigated in medicinal chemistry. The development of radiolabeled protein-inhibitor peptides for molecular imaging and targeted therapy with quickstep towards clinical translation is an interesting and active research field in the radiopharmaceutical sciences. In this article, recent achievements concerning the design, translational research and theranostic applications of structurally-modified small radiopeptides such as prostate-specific membrane antigen (PSMA) inhibitors, fibroblast activation protein (FAP) inhibitors and antagonists of chemokine-4 receptor ligands (CXCR-4-L), with high affinity for cancer-associated target proteins, are reviewed and discussed.

Keywords: Radiolabeled peptides, Inhibitor peptides, Translational radiopeptides, PSMA, FAP, CXCR-4

Rights & PermissionsPrintExport Cite as

Article Details

(E-pub Ahead of Print)
DOI: 10.2174/0929867327666191223121211
Price: $95

Article Metrics

PDF: 8